Development

Systematic, data-driven science coverage · Saturday, August 8, 2026
The AllSci BriefSystematic R&D and deal news. Daily.
Most Read
Business

Pfizer Q2'26: Mevrometostat, tilrekimig and sigvotatug vedotin shape pipeline outlook

Pfizer Q2'26: Mevrometostat, tilrekimig and sigvotatug vedotin shape pipeline outlook
Business

Gilead Q2'26: BIC/LEN nears approval as weekly HIV pipeline expands

Gilead Q2'26: BIC/LEN nears approval as weekly HIV pipeline expands
Business

CSPC and AstraZeneca establish biologics manufacturing joint venture in China

CSPC and AstraZeneca establish biologics manufacturing joint venture in China
Business

Novo Nordisk Q2'26: ZEUS failure overshadows obesity pipeline advances

Novo Nordisk Q2'26: ZEUS failure overshadows obesity pipeline advances
Business

Mironid raises USD 46m to advance first-in-class ADPKD therapy

Mironid raises USD 46m to advance first-in-class ADPKD therapy
More from Development
Dispatch advances synthetic-antigen CAR T platform into first-in-human testing
Development

Dispatch advances synthetic-antigen CAR T platform into first-in-human testing

Dispatch Bio has dosed the first patient in a Phase I study of DISP-10 immunotherapy, a combination approach pairing a tumor-specific virus with an approved...

10h agoVistagen reports exploratory Phase II miss for social anxiety drug candidate
Development

Vistagen reports exploratory Phase II miss for social anxiety drug candidate

South San Francisco-based Vistagen Therapeutics (Nasdaq: VTGN) reported topline results on August 6 from an exploratory Phase II study of fasedienol nasal...

10h agoEdding Genor tries trispecific PD-1/CTLA-4/VEGF antibody against breast cancer
Development

Edding Genor tries trispecific PD-1/CTLA-4/VEGF antibody against breast cancer

Hong Kong-listed Edding Genor Group Holdings Limited (HKEX: 06998) announced on August 6 that the first subject has been dosed in the Phase Ib/II clinical...

11h agoMediar partners with Ono Pharma on fibro-inflammatory discovery
Development

Mediar partners with Ono Pharma on fibro-inflammatory discovery

Boston-based Mediar Therapeutics has entered a collaboration and option agreement with Japan-based Ono Pharmaceutical to develop antibody therapies for...

1d agoBezisterim meets motor and non-motor endpoints in phase II early Parkinson's trial.
Development

Bezisterim meets motor and non-motor endpoints in phase II early Parkinson's trial.

BioVie (Nasdaq: BIVI) reported that bezisterim, its investigational oral anti-inflammatory compound, met prespecified endpoints in a Phase II trial in early...

1d agoLuye clears US bridging milestone for first dual-mechanism TD therapy
Development

Luye clears US bridging milestone for first dual-mechanism TD therapy

Luye Pharma Group (HKEX: 02186) announced on August 5 the successful completion of a US pharmacokinetic (PK) bridging study of LY03015, its investigational...

1d ago
Development

Hengrui, Braveheart's cardiac myosin inhibitor shows strong early efficacy against cardiomyopathy

Hengrui Pharma and Braveheart Bio reported Phase 2 results for HRS-1893 (BHB-1893), a selective small-molecule cardiac myosin inhibitor, in patients with...

1d agoSummit expands ivonescimab's challenge to Keytruda into bladder cancer
Development

Summit expands ivonescimab's challenge to Keytruda into bladder cancer

Summit Therapeutics (Nasdaq: SMMT) announced the initiation of HARMONi-GU1, a Phase II/III trial testing ivonescimab plus Astellas/Pfizer's Padcev...

2d ago
The AllSci BriefSystematic R&D and deal news. Daily.
Forlong moves SC IL-15 superagonist into Phase I in Australia
Development

Forlong moves SC IL-15 superagonist into Phase I in Australia

China-based Forlong Biotechnology has announced approval to initiate a Phase I clinical trial of FL115, an IL-15/IL-15Rα-Fbody fusion protein, administered...

3d agoModerna advances Bundibugyo Ebola mRNA vaccine into Phase I
Development

Moderna advances Bundibugyo Ebola mRNA vaccine into Phase I

Moderna (Nasdaq: MRNA) has dosed the first participants in a Phase I trial of mRNA-1469, its investigational mRNA vaccine against Bundibugyo ebolavirus...

3d agoLeads Biolabs' NewCo Oblenio advances CD19×BCMA×CD3 trispecific into clinic
Development

Leads Biolabs' NewCo Oblenio advances CD19×BCMA×CD3 trispecific into clinic

Oblenio Bio has dosed the first patients in a Phase Ia first-in-human trial of LBL-051, a CD19×BCMA×CD3 tri-specific T-cell engager being evaluated in...

3d agoOtsuka's sibeprenlimab stabilizes kidney function decline to near-baseline rate in IgAN Phase III
Development

Otsuka's sibeprenlimab stabilizes kidney function decline to near-baseline rate in IgAN Phase III

Otsuka reported two-year kidney function data from the Phase III VISIONARY trial of sibeprenlimab (Voyxact) in IgA nephropathy (IgAN) that complete the...

4d agoNovo's ziltivekimab misses cardiovascular endpoint despite biomarker success
Development

Novo's ziltivekimab misses cardiovascular endpoint despite biomarker success

Novo Nordisk's ZEUS trial has delivered a clean failure for ziltivekimab, the company's anti-IL-6 monoclonal antibody, dealing a setback to the hypothesis...

Jul 31CREATE clears Australian ethics review for first-in-human in vivo CAR-T study
Development

CREATE clears Australian ethics review for first-in-human in vivo CAR-T study

Cambridge, Massachusetts-based CREATE Medicines, Inc. has received Human Research Ethics Committee (HREC) approval in Australia to begin a first-in-human...

Jul 31Pfizer's Litfulo succeeds in Phase III vitiligo trials, setting up rivalry with Rinvoq
Development

Pfizer's Litfulo succeeds in Phase III vitiligo trials, setting up rivalry with Rinvoq

Pfizer (NYSE: PFE) reported positive topline Phase III results for ritlecitinib (Litfulo) in nonsegmental vitiligo (NSV), positioning the drug to become the...

Jul 30